Acorn Capital Advisors LLC Makes New $6.76 Million Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)

Acorn Capital Advisors LLC acquired a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,279,800 shares of the company's stock, valued at approximately $6,757,000. Protara Therapeutics comprises approximately 3.7% of Acorn Capital Advisors LLC's investment portfolio, making the stock its 10th largest position. Acorn Capital Advisors LLC owned 6.20% of Protara Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of Protara Therapeutics by 21.0% during the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock worth $311,000 after acquiring an additional 29,514 shares during the last quarter. Bailard Inc. bought a new stake in Protara Therapeutics during the 4th quarter worth about $157,000. Commonwealth Equity Services LLC lifted its position in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after purchasing an additional 17,572 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Protara Therapeutics by 12.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after purchasing an additional 22,301 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Protara Therapeutics during the 4th quarter worth approximately $11,880,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Protara Therapeutics Trading Up 0.1 %

Shares of NASDAQ TARA traded up $0.01 during mid-day trading on Wednesday, reaching $3.38. 129,902 shares of the company's stock were exchanged, compared to its average volume of 783,979. The business has a fifty day simple moving average of $4.01 and a 200 day simple moving average of $4.07. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market capitalization of $130.20 million, a price-to-earnings ratio of -1.20 and a beta of 1.73.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09. Equities research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Insider Transactions at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the sale, the insider now owns 98,861 shares in the company, valued at approximately $447,840.33. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 12.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Lifesci Capital began coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 28th. Cantor Fitzgerald started coverage on Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. Finally, Scotiabank began coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $20.40.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.